Document is current
Any future updates will be listed below
-
Authors
Raven, Alexander https://orcid.org/0000-0003-4409-9543
Gilroy, Kathryn
Jin, Hu https://orcid.org/0000-0002-8657-5686
Waldron, Joseph A.
Leslie, Holly
Munro, June
Hall, Holly
Ridgway, Rachel A.
Ford, Catriona A.
Gulhan, Doga C.
Vlahov, Nikola
Mills, Megan L.
Hartley, Andrew
Anderson, Eve
Bryson, Sheila
Sphyris, Nathalie https://orcid.org/0000-0003-1860-1958
Müller, Miryam
May, Stephanie https://orcid.org/0000-0003-0095-7403
Cadden, Barbara
Nixon, Colin https://orcid.org/0000-0002-8085-2160
Waddell, Scott H.
Guest, Rachel
Boulter, Luke https://orcid.org/0000-0002-7954-6705
Barker, Nick https://orcid.org/0000-0003-3566-4475
Clevers, Hans https://orcid.org/0000-0002-3077-5582
Zhu, Hao https://orcid.org/0000-0002-8417-9698
Ivaska, Johanna https://orcid.org/0000-0002-6802-6739
Strathdee, Douglas https://orcid.org/0000-0003-2959-4327
Miller, Crispin J. https://orcid.org/0000-0003-4341-1283
Jamieson, Nigel B. https://orcid.org/0000-0002-9552-4725
Bushell, Martin
Park, Peter J. https://orcid.org/0000-0001-9378-960X
Bird, Thomas G. https://orcid.org/0000-0002-6120-1581
Sansom, Owen J. https://orcid.org/0000-0001-9540-3010
- License Information
-
More Information
Article History
Received: 19 May 2023
Accepted: 9 October 2025
First Online: 19 November 2025
Competing interests
: O.J.S. receives funding from Novartis, Cancer Research Technology (Cancer Research Horizons), Boehringer Ingelheim and AstraZeneca for other unrelated projects. H.Z. is a cofounder of Quotient Therapeutics and Jumble Therapeutics, advises for Newlimit, Alnylam Pharmaceuticals and receives funding from Chroma Medicines for other unrelated projects. H.C. is the head of PharmaResearch and Early Development at Roche; full disclosure is available at . M.B. has consulted for BIoNTech. All other authors declare no competing interests.
